Source comparison
Receptor Sensitivity Preservation — The DAC vs No DAC Distinction
The addition of a Drug Affinity Complex (DAC) to CJC-1295 extends its half-life from 30 minutes to 6–8 days by covalently binding the peptide to serum albumin. This modification allows once-weekly dosing but fundamentally alters the pharmacodynamic profile. CJ
This comparison does not assign a generated winner or score.
- The addition of a Drug Affinity Complex (DAC) to CJC-1295 extends its half-life from 30 minutes to 6–8 days by covalently binding the peptide to serum albumin. This modification allows once-weekly dosing but fundamentally alters the pharmacodynamic profile. CJC-1295 with DAC produces sustained GHRH receptor occupancy rather than pulsatile activation. Research published in the Journal of Clinical Endocrinology & Metabolism found that sustained GHRH receptor activation for more than 48 continuous hours triggers a compensatory increase in somatostatin release, which suppresses pulsatile GH secretion by 25–40% even while total 24-hour GH output remains elevated.
- This is the critical trade-off: CJC-1295 with DAC produces higher total GH area-under-the-curve (AUC) but at the cost of flattened pulse architecture. The pituitary adapts to sustained stimulation by downregulating receptor density. A 2017 study in Growth Hormone & IGF Research documented a 22% reduction in GHRH receptor expression after 8 weeks of continuous GHRH analog exposure. CJC-1295 No DAC avoids this adaptation because each dose clears within 2–3 hours, allowing somatostatin to reassert inhibitory tone and reset receptor sensitivity before the next administration.
- Ipamorelin's selectivity for GHS-R1a without cortisol or prolactin co-release is the second preservation mechanism. Earlier ghrelin mimetics like GHRP-6 and GHRP-2 activate multiple receptor subtypes, producing cortisol elevations of 40–80% above baseline alongside GH release. Chronic cortisol elevation suppresses GH receptor sensitivity in peripheral tissues and reduces hepatic IGF-1 production. Undermining the anabolic signal the protocol is designed to amplify. Ipamorelin's isolated GH release preserves the hypothalamic-pituitary-liver axis without activating counter-regulatory stress pathways.
- The honest answer: CJC-1295 with DAC works for short-term research applications where convenience outweighs receptor preservation. For protocols extending beyond 8–12 weeks, the No DAC version maintains efficacy without requiring dose escalation to overcome desensitization.